Skip to main content

Table 1 Associations between clinical characteristics of HCC patients from TCGA and three immune subtypes

From: Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma

  Cluster1
(n = 104)
Cluster2
(n = 135)
Cluster3
(n = 132)
P-value
Gender     
 Female 33 (31.7%) 42 (31.1%) 46 (34.8%) 0.788
 Male 71 (68.3%) 93 (68.9%) 86 (65.2%)
Race     
 Asian 52 (50.0%) 52 (38.5%) 54 (40.9%) 0.116
 Black 7 (6.7%) 7 (5.2%) 3 (2.3%)
 White 42 (40.4%) 74 (54.8%) 68 (51.5%)
Alcohol consumption 35 (33.7%) 48 (35.6%) 47 (35.6%) 0.299
HBV 63 (60.6%) 84 (62.2%) 82 (62.1%) 0.172
HCV 21 (20.2%) 22 (16.3%) 18 (13.6%) 0.808
Drug treatment 13 (12.5%) 21 (15.3%) 30 (22.5%) 0.109
AFP     
 AFP < 200 47 (45.2%) 70 (51.9%) 84 (63.6%) 0.018
 AFP > 200 31 (29.8%) 19 (14.1%) 27 (20.5%)
Vascular invasion     
 None 46 (44.2%) 74 (54.8%) 86 (65.2%) 0.057
 Yes 38 (36.5%) 33 (24.4%) 38 (28.8%)
Tumor grade     
 G1 9 (8.7%) 30 (22.2%) 16 (12.1%) 0.053
 G2 50 (48.1%) 57 (42.2%) 70 (53.0%)
 G3 40 (38.5%) 43 (31.9%) 39 (29.5%)
 G4 5 (4.8%) 3 (2.2%) 4 (3.0%)
T stage     
 T1 38 (36.5%) 62 (45.9%) 81 (61.4%) 0.010
 T2 34 (32.7%) 36 (26.7%) 24 (18.2%)
 T3 28 (26.9%) 31 (23.0%) 21 (15.9%)
 T4 4 (3.8%) 5 (3.7%) 4 (3.0%)
M stage     
 M0 75 (72.1%) 92 (68.1%) 99 (75.0%) 0.215
 M1 1 (1.0%) 0 (0%) 3 (2.3%)
 MX 28 (26.9%) 43 (31.9%) 30 (22.7%)
N stage     
 N0 69 (66.3%) 84 (62.2%) 99 (75.0%) 0.103
 N1 2 (1.9%) 2 (1.5%) 0 (0%)
 NX 32 (30.8%) 49 (36.3%) 33 (25.0%)
Pathological stage     
 Stage I 36 (34.6%) 57 (42.2%) 78 (59.1%) 0.002
 Stage II 32 (30.8%) 32 (23.7%) 22 (16.7%)
 Stage III 32 (30.8%) 31 (23.0%) 22 (16.7%)
 Stage IV 1 (1.0%) 1 (0.7%) 3 (2.3%)
  1. Italics font of P-value represented P < 0.05